BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 9209519)

  • 21. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
    Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
    Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.
    Santinami M; Deraco M; Azzarelli A; Cascinelli F; Chiti A; Costagli V; Inglese MG; Manzi R; Quagliolo V; Rebuffoni G; Santoro N; Vaglini M
    Tumori; 1996; 82(6):579-84. PubMed ID: 9061068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion.
    Sijens PE; Eggermont AM; van Dijk PV; Oudkerk M
    NMR Biomed; 1995 Aug; 8(5):215-24. PubMed ID: 8664107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.
    Jakob J; Hohenberger P
    Cancer; 2016 Sep; 122(17):2624-32. PubMed ID: 27197621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
    Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
    J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
    Deroose JP; Burger JW; van Geel AN; den Bakker MA; de Jong JS; Eggermont AM; Verhoef C
    Ann Surg Oncol; 2011 Feb; 18(2):321-7. PubMed ID: 21049306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncological outcome after hyperthermic isolated limb perfusion for primarily unresectable versus locally recurrent soft tissue sarcoma of extremities.
    Vassos N; Brunner M; Perrakis A; Göhl J; Grützmann R; Hohenberger W; Croner RS
    Surg Oncol; 2020 Dec; 35():162-168. PubMed ID: 32882523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF-based isolated limb perfusion in unresectable extremity desmoid tumours.
    Grünhagen DJ; de Wilt JH; Verhoef C; van Geel AN; Eggermont AM
    Eur J Surg Oncol; 2005 Oct; 31(8):912-6. PubMed ID: 16098709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lower limb function and quality of life after ILP for soft-tissue sarcoma.
    Podleska LE; Kaya N; Farzaliyev F; Pöttgen C; Bauer S; Taeger G
    World J Surg Oncol; 2017 Apr; 15(1):84. PubMed ID: 28403880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The oncological outcomes of isolated limb perfusion and neo-adjuvant radiotherapy in soft tissue sarcoma patients - A nationwide multicenter study.
    van Praag VM; Fiocco M; Bleckman RF; van Houdt WJ; Haas RLM; Verhoef C; Grunhagen DJ; van Ginkel RJ; Bonenkamp JJ; van de Sande MAJ
    Eur J Surg Oncol; 2023 Feb; 49(2):339-344. PubMed ID: 36085118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment.
    Sorkin P; Abu-Abid S; Lev D; Gutman M; Aderka D; Halpern P; Setton A; Kudlik N; Bar-On J; Rudich V
    Arch Surg; 1995 Oct; 130(10):1079-84. PubMed ID: 7575120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Vrouenraets BC; Kroon BB; Ogilvie AC; van Geel AN; Nieweg OE; Swaak AJ; Eggermont AM
    Ann Surg Oncol; 1999 Jun; 6(4):405-12. PubMed ID: 10379864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 31Phosphorus-magnetic resonance spectroscopy to assess histologic tumor response noninvasively after isolated limb perfusion for soft tissue tumors.
    Kettelhack C; Wickede Mv; Vogl T; Schneider U; Hohenberger P
    Cancer; 2002 Mar; 94(5):1557-64. PubMed ID: 11920514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors.
    Schienk S; Liénard D; Gerain J; Baumgartner M; Lejeune FJ; Chiquet-Ehrismann R; Rüegg C
    Int J Cancer; 1995 Nov; 63(5):665-72. PubMed ID: 7591283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low-dose tumour necrosis factor-alpha (TNF-alpha) and melphalan in hyperthermic isolated limb perfusion. Results from a pilot study performed in the United Kingdom.
    Hill S; Thomas JM
    Melanoma Res; 1994 Mar; 4 Suppl 1():31-4. PubMed ID: 8038593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
    Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
    Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
    Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
    J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
    Jakob J; von Rege I; Weiss C; Hohenberger P
    Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.